Dr. Spencer Nadolsky joins Ethan on the American Glutton Podcast to dive into the revolutionary impact of GLP-1 drugs on obesity and cardiometabolic health, exploring their benefits, risks, and societal implications. From debunking myths about weight loss to discussing emerging treatments like myostatin inhibitors, they tackle the science and real-world applications head-on. The conversation also touches on the future of these medications, their potential to prevent weight gain, and the importance of combining them with lifestyle changes like resistance training.

SHOW HIGHLIGHTS

00:00 - Introduction and Catching Up

00:35 - Obesity as a Choice and GLP-1 Drugs

01:58 - Misuse of GLP-1s and Social Media Hype

05:08 - The Science Behind GLP-1 and Incretin Effect

07:37 - How GLP-1 Drugs Work for Weight Loss

10:00 - Benefits vs. Risks of GLP-1 Drugs

11:57 - Common Side Effects and Nausea Discussion

13:15 - Fatigue and Anhedonia as Side Effects

14:54 - Fat Cell Memory and Weight Regain

17:41 - GLP-1s as a Breakthrough for Obesity

19:33 - Comparing Risks of GLP-1s to Other Drugs

20:24 - Big Pharma and Advisory Boards

23:57 - Importance of Protein and Resistance Training

27:34 - Myostatin Inhibitors and Muscle Growth

31:39 - Timeline for New Drug Approvals

33:31 - Drug Costs and Accessibility

37:51 - Comparing GLP-1 Drugs and Zepbound

39:57 - Glucagon and Triple Agonist Drugs

41:58 - Future of GLP-1s in Preventing Weight Gain

43:43 - Microdosing and Anti-Inflammatory Effects

44:33 - GLP-1s and Type 1 Diabetes Considerations

48:50 - Historical Context and Obesity Trends

52:37 - Moralizing Weight and Pharmaceutical Solutions

54:03 - Closing Thoughts and Future Support

Hosted on Acast. See acast.com/privacy for more information.